The assays showed high linearity and a limit of detection of 0.001% BCR-ABL1/ABL1, providing a new method to monitor the MRD also in CML patients with atypical transcripts [55]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.